Ipsen today announced the presentation of 14 scientific abstracts across a broad range of neurological conditions at TOXINS 2026, taking place from 14–17 January 2026 in Madrid. The presentations underscore Ipsen’s continued commitment to advancing evidence-based solutions and addressing persistent care gaps in neurology, particularly within movement disorders, while also highlighting investigational areas and emerging clinical tools designed to improve patient outcomes.
The data presented at TOXINS 2026 reflect the depth and diversity of Ipsen’s research portfolio in neurological diseases, with a strong focus on real-world evidence and patient-centered outcomes. Multiple presentations explore the use of Dysport® (abobotulinumtoxinA) across conditions such as post-stroke spasticity, cervical dystonia, blepharospasm, and other movement disorders. Together, these findings add to the growing body of evidence supporting the role of abobotulinumtoxinA in routine clinical practice, while also shedding light on variations in care delivery, treatment persistence, and quality-of-life improvements.
A key highlight of Ipsen’s presence at the conference is the interim analysis from the ongoing EPITOME study. EPITOME is a large, multi-country epidemiological study designed to follow adults aged 18 to 85 years after their first stroke. Its primary objective is to better understand how frequently post-stroke spasticity (PSS) develops and to support earlier identification of this often under-recognized complication. Central to the study is the Post-stroke Spasticity Monitoring Questionnaire (PSMQ), a remote monitoring tool intended to help clinicians detect early signs of spasticity and intervene sooner.
Post-stroke spasticity is a common yet frequently underdiagnosed condition that can significantly limit functional recovery and independence following a stroke. Delays in diagnosis often translate into delayed treatment, which may negatively affect rehabilitation outcomes and long-term quality of life. By enabling structured, remote follow-up, monitoring tools such as the PSMQ have the potential to support earlier clinical decision-making and more timely referral to appropriate interventions.
The interim EPITOME analysis presented at TOXINS 2026 shows that 45.7% of stroke survivors with paresis developed spasticity within one year of their stroke. This figure is higher than the previously documented rate of 39.5%, reinforcing the importance of systematic monitoring during the first year after stroke. These findings align with earlier real-world studies and quality-of-life research demonstrating a substantial care gap in current practice. Despite the burden of PSS, fewer than 1% of stroke survivors receive botulinum toxin type A (BoNT-A) treatment for spasticity in routine clinical settings, highlighting a significant unmet need.
Commenting on the data, Sandra Silvestri, MD, PhD, Executive Vice President and Chief Medical Officer at Ipsen, said the breadth of research presented reflects the company’s mission to improve care for people living with neurological diseases. She noted that the EPITOME study exemplifies Ipsen’s focus on standardized, best-practice follow-up, with the aim of ensuring that people living after a stroke are identified early and receive appropriate, timely care to support recovery and quality of life.
Beyond EPITOME, Ipsen’s TOXINS 2026 program includes a wide range of observational and real-world studies examining clinical practice patterns, patient experiences, and outcomes associated with abobotulinumtoxinA treatment. Several posters explore regional differences in injection guidance techniques and goal attainment following repeat treatments, as well as factors associated with treatment persistence and discontinuation. Other analyses focus on quality-of-life improvements in patients with leg or upper limb spasticity, using both disease-specific and generic assessment tools.
Additional presentations investigate real-world use of BoNT-A across different healthcare systems, drawing on national registries and administrative databases from countries including France and Sweden. These studies provide valuable insights into how botulinum toxin therapies are used in everyday practice, trends over time, and opportunities to optimize patient pathways. Ipsen is also presenting data on the use of BoNT-A in parkinsonian syndromes and hyperkinetic movement disorders, further illustrating the breadth of neurological conditions under investigation.
The company’s scientific program also extends beyond spasticity and movement disorders. One poster outlines the methodology of the BEOND Phase 3 clinical trials evaluating abobotulinumtoxinA for migraine prevention, reflecting Ipsen’s ongoing investment in expanding therapeutic options for people living with chronic neurological conditions. An oral presentation and accompanying poster explore the use of a novel botulinum toxin to investigate intracellular trafficking, highlighting continued innovation at the scientific level.
Dysport® (abobotulinumtoxinA) is an injectable botulinum neurotoxin type A product derived from Clostridium bacteria. It works by inhibiting the transmission of nerve impulses, thereby reducing excessive muscle contractions. Dysport is supplied as a lyophilized powder and has marketing authorization in approximately 90 countries. With more than 30 years of clinical experience and over 18 million treatment-years of patient exposure, it represents a well-established option in the management of multiple neurological conditions. Detailed recommendations for its use are described in the Summary of Product Characteristics and U.S. Prescribing Information.
Through its extensive presence at TOXINS 2026, Ipsen reinforces its commitment to generating robust clinical evidence, closing gaps in neurological care, and supporting clinicians and patients with solutions that address real-world challenges across the continuum of care.
Source link :https://www.ipsen.com/
